In a mere nine months, Eli Lilly accomplished an unprecedented feat: The drug giant took a blood sample from one of the first U.S. patients to recover from Covid-19, identified an antibody that could fight the virus, and created a version of the antibody to treat people with the disease. Riley Griffin spoke to Lilly's CEO David Ricks about the challenges facing the company and its new treatment amid the worsening pandemic.

See omnystudio.com/listener for privacy information.